UAE's Globalpharma Plans Major Expansion With 25 New Healthcare Products Launching This Year
The UAE-based pharmaceutical producer, Globalpharma, which operates under the ownership of Dubai Investments PJSC, recently announced a significant strategy aiming for the year 2025.
This strategic plan includes the release of 25 new products targeting essential health concerns such as diabetes, heart conditions, digestive health, and bone diseases. This initiative is a testament to Globalpharma's dedication to providing quality, affordable healthcare solutions tailored to the changing needs within the region.
Mohammed Saeed Al Raqbani, General Manager at Dubai Investments Industries & Masharie and Board Director at Globalpharma, said, "As the pharmaceutical sector continues to grow, the Group is strategically positioning Globalpharma to capitalize on emerging opportunities. The goal is to not only contribute to the healthcare ecosystem in the region but also to establish Dubai Investments as a significant player in the global pharmaceutical landscape. Through innovation, partnerships, and a focus on patient-centric solutions, we are confident that Globalpharma will continue to elevate its presence and create meaningful impact."
To support its ambitious goals, Globalpharma is bolstering its distribution networks to ensure its innovative products are readily accessible. This effort includes optimizing its delivery systems and establishing new alliances to cater to both healthcare professionals and patients. By tailoring its entry strategies to fit the distinct needs of various regional markets, Globalpharma aims to fortify its position and venture into new markets, thereby ensuring a broad and efficient distribution of its healthcare solutions.
Basem Albarahmeh, Globalpharma's General Manager, outlined the company's strategic priorities, stating, "Our strategic focus in 2025 revolves around innovation, accessibility, and partnerships. The launch of 25 new products across critical therapeutic areas underscores our commitment to meeting the region's healthcare challenges. From enhancing our nutraceutical and women's health portfolios to expanding our market access strategies, we are setting the foundation for long-term growth."
Globalpharma's roadmap to 2025 is fueled by its achievements in 2024, which witnessed the introduction of novel products such as Glovadip (Valsartan + Amlodipine) and RUSET (Rosuvastatin + Ezetimibe) for heart health. The company also launched Uriout (Febuxostat) for chronic gout management and MG21 and CG21, which are inspired by the UAE's rich heritage, featuring ingredients like myrrh, costus, and cloves.
This plan not only aims to meet the healthcare challenges in the region but also positions Dubai Investments as a key player on the global pharmaceutical stage. With a strong emphasis on innovation and accessibility, Globalpharma is poised for continued success and growth, making a meaningful difference in the lives of patients across the region and beyond.
Sign in with Google